Skip to main content

Dyphylline GG Disease Interactions

There are 4 disease interactions with Dyphylline GG (dyphylline / guaifenesin).

Major

Dyphylline (applies to Dyphylline GG) renal dysfunction

Major Potential Hazard, High plausibility.

Dyphylline is eliminated almost entirely by the kidney. Drug accumulation may occur in patients with impaired renal function. Like other methylxanthines, high plasma levels of the drug may be associated with severe cardio- and neurotoxicity, sometimes without any previous warning. Therapy with dyphylline should be administered cautiously in patients with renal impairment. Dosage adjustments may be necessary. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.

References (2)
  1. "Multum Information Services, Inc. Expert Review Panel"
  2. (2001) "Product Information. Lufyllin (dyphylline)." Wallace Laboratories
Major

Methylxanthines (applies to Dyphylline GG) PUD

Major Potential Hazard, High plausibility. Applicable conditions: Peptic Ulcer

Methylxanthines are known to stimulate peptic acid secretion. Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease. Some manufacturers consider their use to be contraindicated under such circumstance.

References (4)
  1. Stoller JL (1985) "Oesophageal ulceration and theophylline." Lancet, 2, p. 328-9
  2. (2001) "Product Information. Theo-Dur (theophylline)." Schering Corporation
  3. Alterman P, Spiegel D, Feldman J, Yaretzky A (1996) "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician, 54, p. 1473
  4. (2001) "Product Information. Lufyllin (dyphylline)." Wallace Laboratories
Moderate

Dyphylline (applies to Dyphylline GG) cardiotoxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tachyarrhythmia, Angina Pectoris, Myocardial Infarction, Post MI Syndrome, Hyperthyroidism, Hypertension

Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart. Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.

References (2)
  1. "Multum Information Services, Inc. Expert Review Panel"
  2. (2001) "Product Information. Lufyllin (dyphylline)." Wallace Laboratories
Moderate

Methylxanthines (applies to Dyphylline GG) GERD

Moderate Potential Hazard, High plausibility. Applicable conditions: Gastroesophageal Reflux Disease

Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus. Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.

References (4)
  1. Stoller JL (1985) "Oesophageal ulceration and theophylline." Lancet, 2, p. 328-9
  2. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
  3. Alterman P, Spiegel D, Feldman J, Yaretzky A (1996) "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician, 54, p. 1473
  4. (2001) "Product Information. Lufyllin (dyphylline)." Wallace Laboratories

Switch to consumer interaction data

Dyphylline GG drug interactions

There are 109 drug interactions with Dyphylline GG (dyphylline / guaifenesin).

Dyphylline GG alcohol/food interactions

There is 1 alcohol/food interaction with Dyphylline GG (dyphylline / guaifenesin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer